Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Símbolo desconocido
Fecha:
Ordernar por:
FechaHoraFuenteTítuloSímboloCompañía
12/06/202406:07Edgar (US Regulatory)Form F-10POS - Post-effective amendment to a F-10EF registrationNYSE:ERFEnerplus Corporation
12/06/202406:07PR Newswire (Canada)Une étude de l'Armée du Salut révèle une augmentation du recours aux banques alimentaires dans un contexte d'insécurité alimentaire persistante
12/06/202406:05Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNYSE:ERFEnerplus Corporation
12/06/202406:05GlobeNewswire Inc.Clearside Biomedical’s Leadership in Suprachoroidal Delivery Featured in Multiple Presentations at the Clinical Trials at the Summit MeetingNASDAQ:CLSDClearside Biomedical Inc
12/06/202406:05GlobeNewswire Inc.Vertex Acquires Artificial Intelligence Tax Capabilities from Ryan, LLCTG:56XVertex Inc
12/06/202406:05PR Newswire (US)Cyngn Highlights Its Proprietary Computer Vision Advancements with NVIDIA Accelerated ComputingNASDAQ:CYNCYNGN Inc
12/06/202406:05PR Newswire (US)REGENXBIO Announces Leadership TransitionNASDAQ:RGNXREGENXBIO Inc
12/06/202406:04Business WireAlliance of Comprehensive Planners (ACP) Shares Details on 2024 Annual Conference
12/06/202406:04PR Newswire (US)Grand Jury: Flood Management "Come Hell or High Water"
12/06/202406:03Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:NATHNathans Famous Inc
12/06/202406:03PR Newswire (US)Growth market USA: Exyte plans to create up to 1,000 new jobs in high-tech facility industry
12/06/202406:03GlobeNewswire Inc.Velocity Clinical Research partners with Luminis Health, moves into oncology in the U.S.
12/06/202406:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAAvidity Biosciences Inc
12/06/202406:02Edgar (US Regulatory)Form PREM14A - Preliminary proxy statements relating to merger or acquisitionNASDAQ:AGBAWAGBA Group Holding Ltd
12/06/202406:02PR Newswire (US)HOW DIVIDED ARE WE?
12/06/202406:02PR Newswire (US)Gotcha Covered announces first location in Indiana
12/06/202406:01Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ABEOAbeona Therapeutics Inc
12/06/202406:01Business WireBrightside Health Expands into Substance Use Disorder, Virtual Intensive Outpatient Treatment
12/06/202406:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BCDAWBioCardia Inc
12/06/202406:00Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNYSE:SEDASDCL EDGE Acquisition Corporation
12/06/202406:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:XRTXXORTX Therapeutics Inc
12/06/202406:00Business WireImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSai™ TechnologyNASDAQ:IPAImmunoPrecise Antibodies Ltd
12/06/202406:00GlobeNewswire Inc.Evergold Closes $1,072,000 Private Placement to Support Follow-up Drilling at Emerging DEM1 Gold-Silver++ Discovery, BC5EG
12/06/202406:00GlobeNewswire Inc.Singing Machine to Acquire SemiCab, a Leading AI Logistics Technology CompanyNASDAQ:MICSSinging Machine Company Inc
12/06/202406:00Business WireVisa Releases Third Annual Money Travels: 2024 Digital Remittances Adoption ReportNYSE:VVisa Inc
12/06/202406:00Business Wire25 Meat and Seafood Companies Enter the Queue for ReposiTrak’s Expanding Traceability NetworkNYSE:TRAKReposiTrak Inc
12/06/202406:00Business WireRiot Comments on Bitfarms’ Adoption of Shareholder-Unfriendly Poison PillNASDAQ:RIOTRiot Platforms Inc
12/06/202406:00Business WirePritzker Private Capital Names Anna Edgcomb and Alyson Brown Vice Presidents
12/06/202406:00Business WireFoundation Medicine Announces Partnership with Repare Therapeutics to Provide Genomic Profiling Services to Support Clinical Trials and to Develop Companion Diagnostic for Lunresertib
12/06/202406:00Business WireAllay Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application to Initiate Pivotal Phase 2B Trial of ATX101 for the Treatment of Post-Surgical Pain Following Total Knee Replacement Surgery